Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Chandrakanth Are

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7822-8898; OpenAlex author ID A5077137796. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 4 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 20

  1. Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes. Last author DOI 10.1007/s12029-025-01183-2↗
  2. Global trends in the incidence and mortality of pancreatic cancer based on geographic location, socioeconomic status, and demographic shift. Last author DOI 10.1002/jso.27462↗
  3. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗
  4. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Co-author DOI 10.1097/sla.0000000000003568↗
  5. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP. Co-author DOI 10.1245/s10434-020-09460-z↗
  6. Another Potential Benefit of Neoadjuvant Therapy in Pancreatic Cancer: Reduction in Postoperative Readmission Rates. First author DOI 10.1245/s10434-020-09474-7↗
  7. Factors Predictive of Reoperation After Pancreaticoduodenectomy for Pancreatic Cancer. Last author DOI 10.1007/s13193-019-00913-w↗
  8. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.radonc.2018.11.002↗
  9. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… Co-author DOI 10.1097/coc.0000000000000599↗
  10. Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials? Last author DOI 10.1245/s10434-019-07787-w↗
  11. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Co-author DOI 10.18632/oncotarget.25036↗
  12. Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data. Last author DOI 10.1002/jso.24472↗
  13. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospe… Co-author DOI 10.1016/j.radonc.2016.12.030↗
  14. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1038/ajg.2016.482↗
  15. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. Last author DOI 10.1186/s12957-017-1240-2↗
  16. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. Co-author DOI 10.1002/jso.24410↗
  17. Borderline resectable pancreatic cancer. Co-author DOI 10.1007/s13193-014-0374-8↗
  18. Current status and future directions in the management of pancreatic cancer. Co-author DOI 10.1007/s13193-015-0378-z↗
  19. Prospects of miRNA-based therapy for pancreatic cancer. Co-author DOI 10.2174/13894501113149990181↗
  20. Prognostic estimator of survival for patients with localized and extended pancreatic ductal adenocarcinoma. Co-author DOI 10.4137/cin.s11496↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mashaal Dhir · 3 shared papers, 2017–2025 · strength 0.66
  2. Bradley Norman Reames · 3 shared papers, 2021–2022 · strength 0.43
  3. Robert W. Krell · 3 shared papers, 2021–2022 · strength 0.43
  4. Lynette M. Smith · 5 shared papers, 2016–2019 · strength 0.40
  5. Logan R. McNeil · 2 shared papers, 2021–2022 · strength 0.31
  6. Premila Devi Leiphrakpam · 1 shared paper, 2025 · strength 0.30
  7. Prateek Sharma MD · 1 shared paper, 2023 · strength 0.26
  8. Jin Peng He · 2 shared papers, 2021–2022 · strength 0.25
  9. Georgios Gemenetzis · 2 shared papers, 2021–2022 · strength 0.25
  10. Christopher Lee Wolfgang · 2 shared papers, 2021–2022 · strength 0.25
  11. Matthew John Weiss · 2 shared papers, 2021–2022 · strength 0.25
  12. Massimo Falconi · 2 shared papers, 2021–2022 · strength 0.25
  13. Vincent P. Groot · 2 shared papers, 2021–2022 · strength 0.25
  14. Alex B. Blair · 2 shared papers, 2021–2022 · strength 0.25
  15. Vivek Verma · 3 shared papers, 2017–2019 · strength 0.24
  16. Chi H. Lin · 3 shared papers, 2017–2019 · strength 0.24
  17. Asish Patel · 3 shared papers, 2015–2017 · strength 0.22
  18. Bradley R. Hall · 2 shared papers, 2018–2019 · strength 0.20
  19. Surinder K. Batra · 3 shared papers, 2013–2018 · strength 0.18
  20. Jane L. Meza · 2 shared papers, 2019 · strength 0.17
  21. Jean L. Grem · 2 shared papers, 2019 · strength 0.17
  22. Anthony R. Ferrantella · 1 shared paper, 2019 · strength 0.16
  23. Vikas Dudeja · 1 shared paper, 2019 · strength 0.16
  24. Apar Kishor Ganti · 2 shared papers, 2017–2018 · strength 0.16
  25. Michael Anthony Hollingsworth · 2 shared papers, 2017–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.